Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

被引：19
|
作者：
Juric, Dejan
Munster, Pamela N.
Campone, Mario
Ismail-Khan, Roohi
Garcia-Estevez, Laura
Hamilton, Erika Paige
Becerra, Carlos
De Boer, Richard H.
Hui, Rina
Goncalves, Anthony
Wang, Yingbo
Dhuria, Shyeilla V.
Kalimi, Ghulam H.
Lorenc, Karen Cristina Rodriguez
Mayer, Ingrid A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Inst Cancerol Ouest Rene Gauducheau, St Herblain, France
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL USA
[5] Ctr Integral Oncol Clara Campal, START Dept, Madrid, Spain
[6] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[7] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[8] Royal Melbourne Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[9] Westmead Hosp, Sydney, NSW, Australia
[10] Univ Sydney, Sydney, NSW, Australia
[11] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Vanderbilt Ingram Canc Ctr, Breast Canc Program, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
568
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
    Sonke, G. S.
    Hart, L. L.
    Campone, M.
    Erdkamp, F.
    Janni, W.
    Verma, S.
    Villanueva, C.
    Jakobsen, E.
    Alba, E.
    Wist, E.
    Favret, A. M.
    Bachelot, T.
    Hegg, R.
    Wheatley-Price, P.
    Souami, F.
    Sutradhar, S.
    Miller, M.
    Germa, C.
    Burris, H. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S1 - S2
  • [2] Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2-advanced breast cancer
    Munster, P.
    Ismail-Khan, R.
    Garcia-Estevez, L.
    Mayer, I. A.
    Becerra, C.
    Hamilton, E.
    De Boer, R.
    Wardley, A. M.
    Im, S-A
    Teixeira, L.
    Wang, Y.
    Su, F.
    Germa, C.
    Hirawat, S.
    Juric, D.
    CANCER RESEARCH, 2017, 77
  • [3] Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).
    Munster, Pamela N.
    Hamilton, Erika Paige
    Franklin, Catherine
    Bhansali, Suraj
    Wan, Kitty
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2-breast cancer: Safety, preliminary efficacy and molecular analysis
    Juric, Dejan
    Hamilton, Erika
    Garcia Estevez, Laura
    De Boer, Richard H.
    Mayer, Ingrid
    Campone, Mario
    Asano, Shizuka
    Bhansali, Suraj
    Zhang, Vickie
    Hewes, Becker
    Munster, Pamela
    CANCER RESEARCH, 2015, 75
  • [5] Phase Ib/Il study of ribociclib and alpelisib and letrozole in ER+, HER2-breast cancer: Safety, preliminary efficacy and molecular analysis
    Juric, D.
    Ismail-Khan, R.
    Campone, M.
    Garcia-Estevez, L.
    Becerra, C.
    De Boer, R.
    Hamilton, E.
    Mayer, I. A.
    Hui, R.
    Lathrop, K. I.
    Pagani, O.
    Asano, S.
    Bhansali, S. G.
    Zhang, V.
    Hewes, B.
    Munster, P.
    CANCER RESEARCH, 2016, 76
  • [6] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [9] Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
    Jhaveri, Komal
    Lim, Elgene
    Jeselsohn, Rinath
    Ma, Cynthia
    Hamilton, Erika
    Osborne, Cynthia
    Bhave, Manali
    Kaufman, Peter
    Beck, J. Thaddeus
    Manso, Luis
    Parajuli, Ritesh
    Wang, Hwei-Chung
    Tao, Jessica
    Dhakal, Ajay
    Pierga, Jean-Yves
    Lu, Yen-Shen
    Larson, Tim
    Gilarranz, Yolanda Jerez
    Ismail-Khan, Roohi
    Bacchion, Francesca
    Karacsonyi, Claudia
    Li, Yujia
    Estrem, Shawn T.
    Nguyen, Bastien
    Beeram, Muralidhar
    CANCER RESEARCH, 2024, 84 (09)
  • [10] RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease
    Kenis, C.
    Ponde, N. F.
    Decoster, L.
    de Azambuja, E.
    Jerusalem, G.
    Neven, P.
    Dal Lago, L.
    Denys, H.
    Vuylsteke, P.
    Duhoux, F. P.
    Wildiers, H.
    ANNALS OF ONCOLOGY, 2019, 30
12345